Anti-GCC Antibody-Drug Conjugate MLN0264

Known as: MLN0264 
An antibody-drug conjugate (ADC) containing a monoclonal antibody directed against guanylyl cyclase C (GCC or GUCY2C) conjugated to… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2016-2018
01220162018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Guanylyl cyclase C (GCC) is a cell-surface protein that is expressed by normal intestinal epithelial cells, more than 95% of… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2018
2018
PURPOSE This phase 1 dose-escalation portion of the study evaluated the safety, pharmacokinetics (PK), and antitumor activity of… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2017
2017
Background This phase II open-label, multicenter study evaluated the efficacy, safety, and tolerability of TAK-264 in previously… (More)
  • figure 1
  • table 2
  • table 1
  • table 3
Is this relevant?
Review
2017
Review
2017
Antibody-directed cancer chemotherapy in the form of antibody-drug conjugates (ADCs) may improve the therapeutic index with the… (More)
Is this relevant?
2017
2017
Background The first-in-class antibody–drug conjugate TAK-264 (formerly MLN0264) consists of an antibody targeting guanylyl… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
Is this relevant?
2016
2016
PURPOSE To assess the safety, tolerability, and preliminary antitumor activity of the investigational anti-guanylyl cyclase C… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?